Interstitial cystitis is marked by the appearance of glomerulations or pinpoint hemorrhages during hydro-distension

Interstitial Cystitis

Interstitial Cystitis (IC) is a chronic inflammatory condition of unknown origin. According to the NIH, up to 7.9M Americans—mostly women—suffer the debilitating symptoms of IC, which may include:

Today, IC patients are treated with amitryptiline, Elmiron, intravesical cocktails of steroids, local anesthetics, immunosuppressive drugs, and narcotic analgesics. Each of these approaches has significant limitations. LP-08 is an empty lipsomal drug that coats the bladder lining to reduce inflammation and promote healing.
LP-08

Overactive Bladder

Overactive Bladder (OAB) is a common disorder whose symptoms include:

While not life-threatening, OAB can greatly diminish a patient’s quality-of-life. Of the nearly 30 million Americans who suffer from OAB, most are treated orally with medications of dubious value. The large segment of this population has refractory OAB; their illness is unresponsive to oral medication. This unmet medical need represents a market worth between $400 million and $800 million per year. Other treatment options can be time-consuming, invasive, and painful. These include repeated injections of botulinum toxin directly into the bladder wall and various types of nerve stimulation. All require a cytoscopic procedure and may cause serious side effects.

LP-09 is a liposomal formulation of botulinum toxin. It has proven safe and effective for relieving symptoms of refractory OAB and can be administered in an outpatient procedure.

LP-09

Hemorrhagic Cystitis

Hemorrhagic cystitis (HC) is an inflammatory illness marked by chronic bleeding in the bladder. It is a common side-effect radiation and chemotherapy used to treat cancers of the pelvic area—prostate, ovarian, cervical, bladder, and colorectal. Because the bladder exhibits slow cell-turnover, HC can emerge months or years after such procedures.

Unless managed sufficiently, advanced HC can require a cystectomy, the surgical removal of the bladder. In some cases, the condition is fatal. HC places a significant burden on patients and the healthcare system, and can be devastating to patients who are already fighting a malignancy.

Today, the most effective option for treating HC is hyperbaric oxygen (HBO) therapy. This process requires patients to sit in a pressurized room resembling an airline fuselage for long periods of time. HBO therapy is widely unavailable and expensive, ranging from $15k and $50k per treatment.

LP-10 (liposomal tacrolimus) has demonstrated proof-of-concept in animal models of both chemotherapy- and radiation-induced cystitis.

LP-10